Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. Immunotherapy. University Medical Center Mannheim, Mannheim, Germany



Survival: 11.0 months
   
Toxicity Grade: 5
   
Treatments: Chemotherapy
Immunotherapy
   
Drugs:
Country: Germany
   
City/State/Province: Mannheim
   
Hospital: University Medical Center Mannheim
   
Journal: Link
   
Date: 4/2011

Description:
Patients:
This study involved non-small cell lung cancer patients that had not received prior chemotherapy. Patients were divided into 2 separate treatment groups. Group A consisted of 416 patients with a median age of 60 years and 70.7% were male. Group B had 423 patients with a median age of 60 years and 70.2% were male.

Treatment:
Group A was treated with the chemotherapy agents cisplatin and gemcitabine in addition to the immunotherapy agent PF-3512676, which triggers an anti-tumor immune response.

Patients in group B were treated with cisplatin and gemcitabine only.

Toxicity:
Treatment-related deaths were reported for group A from causes including bleeding, anemia, dehydration, and neutropenia. Severe flu-like symptoms were also reported.

For group B, treatment-related death due to bleeding was reported. Also, neutropenia and thrombocytopenia of grade 3 or greater was reported.

Results:
The median overall survival for groups A and B was, 11.0 and 10.7 months, respectively.

Support:
This study was supported by Pfizer, makers of PF-3512676 (called ProMune).

Correspondence: Dr. C. Manegold; email: Prof.Manegold@t-online.de

E-mail to a Friend Email Physician More Information